FirmAtlas
Company handbook · CRL · Prepared by FirmAtlas · firmatlas.app · printed 2026-10-16
CRL · CIK 1100682 · LATEST FILING: 10-Q JUN '26 · FILED AUG 5, 2026
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
$300.15
−6.09 (−1.99%)
Close, Oct 16, 2026 · 52-week $146–333
Last fiscal year
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported revenue of $4.0B for the year ended Dec 27, 2025 (FY25), down 0.9% from FY24. Net loss was $144M, operating cash flow $738M and free cash flow $518M. Source: 10-K filed Feb 18, 2026.
Market cap
$14.8B
EV/EBITDA
39.0x
P/B
5.2
ROIC
0.5%
Revenue 1Y
−0.9%/yr
EPS 1Y
n/m
Shares 1Y
−4%
Loading chart…
Median
Daily closes, split-adjusted · ratios at each fiscal year end
Company
CEOJames C. Foster
HQWilmington, MA
AuditorPricewaterhouseCoopers LLP
Employees19,700
Year endsDecember
Revenue by segment · FY25
Discoveryand Safety Assessment60%
Research Models And Services21%
Manufacturing Support19%
Compounded growth & averages
10Y
5Y
3Y
TTM
Share price
14.1%
−5.7%
15.9%
71.6%
Upgrade to see 10 years
Share price: yearly compound rate of the traded close; the last column is the past year.
Where the cash went · FY24–FY25
$937M deployed
Capex
$452M
48.2%
Acquisitions
$5M
0.6%
Buybacks
$480M
51.2%
Operating cash flow over the period: $1.5B. Total debt changed by −$104M.
Growth engines
How much of the profit growth came from new investment, and how much from running the business better.
Upgrade to see 10 years
Financials
Last 2 years · Upgrade to see 10 years · USD millions · each year opens its 10-K · FY25 = year ended Dec 27, 2025 · change vs previous year
Last 4 quarters · USD millions · quarter-end month shown · change vs same quarter a year earlier
TTM = the last four quarters, to Jun '26. Balance-sheet rows show that latest quarter. “—” where the quarters do not add up to the annual figures. No TTM for cash: our quarterly rows do not hold short-term investments yet, and annual cash includes them.
Income
Revenue
4,050
4,015−0.9%
3,999
YoY
−0.9%
Operating income
227
25−88.9%
90
Operating margin
5.6%
0.6%−5.0 pp
—
EBITDA
589
428−27.3%
—
EBITDA margin
14.5%
10.7%−3.9 pp
—
Interest expense
126
107−15.3%
—
Interest coverage
4.66x
4.00x−0.66x
—
Net income
22
(144)−750.1%
(238)
YoY
−750.1%
Net margin
0.5%
−3.6%−4.1 pp
—
EPS (diluted, $)
0.20
−2.91−1555.0%
−4.85
YoY
−1555.0%
Balance sheet
Total assets
7,528
7,135−5.2%
7,532
Cash & short-term investments
206
216+5.1%
—
Accounts receivable
721
709−1.7%
—
Inventory
279
299+7.4%
—
Net PP&E
1,604
1,655+3.2%
—
Other assets
4,719
4,256−9.8%
—
Total liabilities
4,067
3,971−2.4%
4,693
Accounts payable
140
149+6.0%
—
Total debt
2,240
2,136−4.6%
2,620
Other liabilities
1,686
1,686−0.0%
—
Shareholders’ equity
3,462
3,165−8.6%
2,840
Total liabilities = total assets − shareholders’ equity, so it includes minority interest where a company has one.
Cash flow statement · as filed
Cash from operations
735
738+0.4%
582
Net income
25
(142)−662.1%
—
Depreciation & amortization
362
403+11.5%
—
Stock-based compensation
70
71+1.7%
—
Working capital & other
278
405+46.0%
—
Cash from investing
(245)
(209)n/m
—
Capex
(233)
(219)n/m
—
Acquisitions
(5)
0n/m
—
Investments bought
(53)
(20)n/m
—
Investments sold / matured
42
9−78.2%
—
Other investing
5
21+357.4%
—
Cash from financing
(551)
(537)n/m
—
Debt raised
1,082
1,228+13.5%
—
Debt repaid
(1,494)
(1,349)n/m
—
Buybacks
(119)
(361)n/m
—
Shares issued
24
0.7−97.0%
—
Other financing
(43)
(55)n/m
—
Net change in cash
(79)
10n/m
—
Free cash flow (OCF − capex)
502
518+3.4%
371
Where the cash went
Operating cash flow
735
738+0.4%
582
Reinvested in the business
238
219−8.1%
—
% of operating cash flow
32.5%
29.7%
Capex
233
219−5.9%
212
Acquisitions
5
0−100.0%
—
Free cash flow
502
518+3.4%
371
YoY
+3.4%
Returned to shareholders
119
361+202.6%
—
% of free cash flow
23.8%
69.6%
Buybacks
119
361+202.6%
—
Change in total debt
—
(104)
—
Cash left over
—
54
—
FCF conversion (FCF ÷ net income)
2259.2%
—
—
Owner earnings
—
40
—
Owner earnings margin
—
1.0%
—
Returns & ratios
ROIC (all capital)
1.7%
0.5%−1.2 pp
—
ROIC (operating)
3.7%
1.0%−2.7 pp
—
Net debt / EBITDA
3.45x
4.48x+1.03x
—
Debt / equity
0.65x
0.68x+0.03x
—
ROE
0.6%
−4.6%−5.2 pp
—
ROA
0.3%
−2.0%−2.3 pp
—
ROCE
3.5%
0.4%−3.1 pp
—
NOPAT
91
25−72.3%
—
Invested capital (operating)
2,463
2,514+2.1%
—
Invested capital (all)
5,496
5,085−7.5%
—
Reinvestment rate
—
203.6%
—
Net debt is 4.5x EBITDA (FY25).
Income
Sep '25
Dec '25
Mar '26
Jun '26
Revenue
1,005
994
996
1,004
vs year-ago quarter
Operating income
134
(283)
120
120
Net income
54
(277)
(15)
(1)
vs year-ago quarter
Net margin
5.4%
−27.8%
−1.5%
−0.1%
EPS (diluted, $)
1.10
−5.62
−0.30
−0.03
vs year-ago quarter
Balance sheet
Sep '25
Dec '25
Mar '26
Jun '26
Total assets
7,514
7,135
7,730
7,532
Cash & equivalents
209
216
198
241
Total debt
2,185
2,136
2,663
2,620
Shareholders’ equity
3,405
3,165
2,941
2,840
Cash flow
Sep '25
Dec '25
Mar '26
Jun '26
Operating cash flow
214
148
41
180
Capex
36
89
56
31
Free cash flow
178
59
(15)
149
vs year-ago quarter